US biosimilar norms to keep local drug cos in good health

With the new regulations set by the US FDA, the pathway to creating biosimilars will be both faster and more cost-effective. This development is a game changer for Indian firms like Biocon and Dr Reddy's Laboratories, allowing them to provide more economical medicines to patients.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/FT7B2hj
via IFTTT